Home » News » CHMP Recommends 'Januvia(R)'(sitagliptin),...
CHMP Recommends 'Januvia(R)'(sitagliptin), From MSD, For Restricted First Line Use In European Union
Merck & Co., Inc. (Whitehouse Station, N.J., U.S.A.), which operates in many countries as Merck Sharp & Dohme (MSD), has received a positive opinion from the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) recommending restricted first line use of 'Januvia' (sitagliptin) for the treatment of type 2 diabetes.
Read full article @ MedicalNewsToday
Read Also Other "Diabetes" News
- DRSI Launches The First And Only Diabetes Energy Formula Specifically Created For Diabetics To Counter Their No. 1 Complaint: Fatigue Diabetica Research Solutions, Inc. (DRSI) http://www.drsirestoreenergy.com:...
- Efforts To Create Treatment Guidelines Are Often Complicated The development of treatment guidelines for illnesses such as diabetes is a...
- Insulin Glargine - European Medicines Agency Update On Safety The European Medicines Agency's Committee for Medicinal Products for Human...